<DOC>
	<DOCNO>NCT01812096</DOCNO>
	<brief_summary>Intravenous injection standard administration route bortezomib ; however , subcutaneous administration important alternative . We want compare pharmacokinetic subcutaneous versus intravenous bortezomib approve 1â€¢3 mg/m2 dose twice per week , days1 , 4 , 8 11 21-day cycle , schedule newly diagnose patient multiple myeloma .</brief_summary>
	<brief_title>Study Subcutaneous Versus Intravenous Administration Bortezomib Patients With Multiple Myeloma China</brief_title>
	<detailed_description>The new diagnosed multiple myeloma patient randomize receive bortezomib standard intravenous bolus ( n=10 ) subcutaneous injection ( n=10 ) recommend dose schedule ( 1.3 mg/m2 ) , day 1 , 4 , 8 , 11 ; eight 21-day cycle ) . Patients discontinue treatment due progressive disease , insufficient efficacy , unacceptable toxicity , serious protocol violation . Dose modification specify unexpected pharmacokinetic observation toxicity . Bortezomib-related neuropathic pain and/or peripheral sensory neuropathy manage use establish dose-modification guideline . Blood sample pharmacokinetic/pharmacodynamic analysis collect day 1 11 , cycle 1 : bortezomib administration , 2 , 5 , 15 , 30 , 60 min , 2 , 4 , 6 , 10 , 24 , 32 , 48 , 72 hour post-dosing . Pharmacodynamic analyse perform use whole-blood 20S proteasome specific activity inhibition assay .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Must Multiple Myeloma Proved Laboratory Tests Must ability observe efficacy event Patient must ability understand willingness provide write informed consent study relate procedure perform If uncontrolled intercurrent illness include ongoing active infection , heart failure , unstable angina pectoris , psychiatric illness/social situation study requirement If severe sideeffects bortezomib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>bortezomib</keyword>
	<keyword>Subcutaneous</keyword>
</DOC>